Cetuximab for the Treatment of Colorectal Cancer

摘要: Background Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity colorectal cancers that express EGFR. Methods From December 2003 to August 2005, 572 patients who had cancer expressing immunohistochemically detectable EGFR and been previously treated with a fluoropyrimidine, irinotecan, oxaliplatin or contraindications treatment these drugs underwent randomization initial dose of 400 mg cetuximab per square meter body-surface area followed by weekly infusion 250 plus best supportive care (287 patients) alone (285 patients). The primary end point was overall survival. Results In comparison alone, associated significant improvement in survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 0.92; P=0.005) progression-free disease pr...